Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313287" target="_blank" >RIV/00216208:11110/15:10313287 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/15:10313287 RIV/00064203:_____/15:10313287 RIV/00023728:_____/15:#0005040

Výsledek na webu

<a href="http://dx.doi.org/10.1093/rheumatology/kev229" target="_blank" >http://dx.doi.org/10.1093/rheumatology/kev229</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/rheumatology/kev229" target="_blank" >10.1093/rheumatology/kev229</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience

Popis výsledku v původním jazyce

Objectives. Immune-mediated necrotizing myopathy (IMNM) is characterized by the predominant presence of necrotic muscle fibres in muscle biopsy and variable response to immunosuppressive treatment. The aims of this study were to analyse the temporal trend of IMNM incidence in our centre over the past 10 years and to explore the role of statins as possible causative agents. Methods. A retrospective evaluation of muscle biopsy results, clinical and laboratory data, including antibody associations of all patients with idiopathic inflammatory myopathy newly diagnosed between 2004 and June 2014, was performed. Available sera were tested for the presence of anti-3-hydroxy-3methylglutaryl coenzyme A reductase (anti-HMGCR) autoantibodies. Results. Of 357 biopsied patients, 233 fulfilled criteria for inflammatory/immune-mediated myopathy, including 27 (11.6%) classified as IMNM. There were no patients with IMNM diagnosed between 2004 and 2007; subsequently, two to three cases of IMNM per year w

Název v anglickém jazyce

Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience

Popis výsledku anglicky

Objectives. Immune-mediated necrotizing myopathy (IMNM) is characterized by the predominant presence of necrotic muscle fibres in muscle biopsy and variable response to immunosuppressive treatment. The aims of this study were to analyse the temporal trend of IMNM incidence in our centre over the past 10 years and to explore the role of statins as possible causative agents. Methods. A retrospective evaluation of muscle biopsy results, clinical and laboratory data, including antibody associations of all patients with idiopathic inflammatory myopathy newly diagnosed between 2004 and June 2014, was performed. Available sera were tested for the presence of anti-3-hydroxy-3methylglutaryl coenzyme A reductase (anti-HMGCR) autoantibodies. Results. Of 357 biopsied patients, 233 fulfilled criteria for inflammatory/immune-mediated myopathy, including 27 (11.6%) classified as IMNM. There were no patients with IMNM diagnosed between 2004 and 2007; subsequently, two to three cases of IMNM per year w

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Rheumatology

ISSN

1462-0324

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

2010-2014

Kód UT WoS článku

000364760700012

EID výsledku v databázi Scopus

—